We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
FUJIREBIO

Download Mobile App





World’s First AI Rapid Antigen Test System for COVID-19 Delivers Highly Accurate Results on Smartphone Within 5-8 Minutes

By LabMedica International staff writers
Posted on 23 Feb 2021
Print article
Image: LooK SPOT App (Photo courtesy of AETOSWire)
Image: LooK SPOT App (Photo courtesy of AETOSWire)
The world’s first rapid COVID-19 antigen test system using artificial intelligence (AI) could revolutionize medical diagnostics, enabling early disease detection with consistent and accurate results.

Laipac Technology Inc. (Ontario, Canada), a developer of IoMT (Internet of Medical Things), has entered into a partnership with YAS Pharmaceuticals LLC (Abu Dhabi, UAE) and Pure Health LLC (Dubai, UAE) to launch the European CE-IVD approved LooK SPOT AI COVID-19 Antigen Rapid Test System.

The LooK SPOT solution is an intelligent and innovative way to deploy technologies to better protect the health of people across the region. Being able to have a quick and accurate COVID-19 diagnosis can interrupt transmission, aid clinical management, and help proper allocation of resources to isolation. The smartphone-based diagnostic device with lateral flow immunoassay is intended for the qualitative detection of nucleocapsid protein from SARS-CoV-2 in nasal swabs. The LooK SPOT Artificial Intelligence Ecosystem revolutionizes medical diagnostics, enabling early disease detection with consistent and accurate results.

LooK SPOT AI COVID-19 Antigen Rapid Test uses the nasal sample collected from one inch in the nostril. It uses AI technology to deliver real-time test results within 5 to 8 minutes with 97.4% sensitivity and 98.3% specificity in detecting the SARS-CoV-2 virus. The LooK SPOT COVID-19 Antigen Rapid Test can also detect the new variant of the SARS-CoV-2 virus which was first identified in the UK and South Africa.

The LooK PASS App can be downloaded from Apple or Google stores, to scan the LooK COVID-19 antigen cassette before the test, and test results can be received on smartphones within 5 to 8 minutes. Negative test results generate a QR code on the app which may be used as a pass to enter a facility, events and gatherings or used for transport facilities. Via Pure Health, LooK SPOT will be able to provide a full API integration with multiple IT applications and travel applications for real time reporting.

"LooK SPOT's AI Algorithm has high accuracy and can identify the color signal on tests in low positive cases when human eyes cannot, therefore eliminating the human error and manual process done with other antigen tests available in the market. LooK SPOT reduces healthcare responders' cognitive load by providing accurate test results in an easy-to-read format. LooK SPOT has been designed with a tactical edge to fight COVID-19," said Diego Lai, Co-founder and CEO of Laipac.

Related Links:
Laipac Technology Inc.
YAS Pharmaceuticals LLC
Pure Health LLC


New
Gold Supplier
Clinical Chemistry Series
Clinical Chemistry Series
New
Gold Supplier
SARS-CoV-2 Assay
SARS-CoV-2 UTAB FS
COVID-19 Positive Control
STAT-NAT COVID-19 Positive Control
Respiratory SARS-CoV-2 Panel
QIAstat-Dx Respiratory SARS-CoV-2 Panel

Print article

Channels

Molecular Diagnostics

view channel
Image: Histopathologic image from a patient with Li Fraumeni syndrome showing accumulation of mutant TP53 in tumoral cells (Photo courtesy of Thierry Soussi, PhD).

Clinical Germline Testing Evaluated for Pediatric Cancer Patients

Pediatric cancer is rare, with fewer than 10,000 solid tumors diagnosed in children annually in the USA. Previous studies interrogating germline predisposition broadly across pediatric cancer types have... Read more

Industry

view channel
Illustration

Mindray and Tencent AI Lab to Jointly Develop AI Products for Blood Disease Screening and In Vitro Diagnosis

Shenzhen Mindray Biomedical Electronics Co., Ltd. (Shenzhen, China) has signed an AI cooperation framework agreement with Tencent AI Lab (Shenzhen, China) to jointly develop AI products for blood cell... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.